IMAB
$38.22
I-Mab ADR
($.95)
(2.43%)
IMAB
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.53)
Revenue:  $0.00 Mil
Monday
Aug 31
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when IMAB reports earnings?
Beat
Meet
Miss

Where is IMAB's stock price going from here?
Up
Flat
Down
Stock chart of IMAB
Analysts
Summary of analysts' recommendations for IMAB
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.